Ritchey, Mary E.
Wang, Jingjun
Young, Jessica C.
Chandra, Rajat
Carrera, Adam
Goti, Noelia
Horn, John R.
Girman, Cynthia J.
Funding for this research was provided by:
Urovant Sciences
Article History
Accepted: 29 September 2022
First Online: 2 December 2022
Declarations
:
: Funding for this analysis and for medical writing and editorial assistance was provided by Urovant Sciences (Irvine, CA).
: MER was a consultant to CERobs Consulting, LLC, a consulting firm that was contracted by Urovant Sciences and consults with other pharmaceutical companies, at the time the work was conducted. JW and RC are employees of Sumitovant Biopharma, Inc. JCY is a consultant to CERobs Consulting, LLC, a consulting firm that was contracted by Urovant Sciences and consults with other pharmaceutical companies. AC is an employee of Urovant Sciences and of Duke Health. NG is an employee of Urovant Sciences. JRH is a co-author and publisher of <i>The Top 100 Drug Interactions: A Guide to Patient Management</i> and a consultant to Urovant Sciences and Seegnal US. CJG is the President of CERobs Consulting, LLC, a consulting firm that consults with pharmaceutical companies and was contracted by Urovant Sciences.
: This retrospective database analysis used deidentified claims data from the IQVIA PharMetrics<sup>®</sup> Plus database, which is compliant with the Health Insurance Portability and Accountability Act to protect patient privacy.
: Not applicable.
: Not applicable.
: Not applicable.
: Datasets generated and/or analyzed during the current study are available from Sumitovant Biopharma, Inc. (Jingjun Wang; monica.wang@sumitovant.com), through licensing with IQVIA, Inc, and requests will be considered from qualified researchers on a case-by-case basis with the condition of IQVIA approval.
: MER, JW, JCY, RC, AC, NG, and CJG developed the protocol. JW and RC analyzed the data. All authors contributed to the interpretation of data, revised the manuscript for intellectual content, and read and approved the final version.